Vitamin K2 and Bone and Heart Health: What Does the Research Actually Confirm?

Vitamin K2 (menaquinone) differs from the better-known vitamin K1 mainly in where it acts most strongly in the body — while K1 concentrates mainly on blood clotting in the liver, K2 activates proteins that regulate calcium metabolism outside the liver, including osteocalcin (which builds bone) and MGP protein, or matrix Gla-protein (which inhibits calcium deposition in blood vessel walls). This dual mechanism led to the popular "calcium redirection" hypothesis — that K2 directs calcium to where it's needed (bones) rather than where it causes harm (arteries).

This is an attractive, biologically coherent hypothesis, but two separate promises require two separate bodies of evidence — one concerning bone mineral density, the other vascular and valvular calcification. Separating these two threads is crucial, because, as the newest research shows, the evidence supporting them is far from equally strong.

The most compelling source on vitamin K2's effect on bones is the 2022 meta-analysis by Ma and colleagues, published in Frontiers in Public Health, focused on postmenopausal women — the group at highest risk of osteoporosis, described in more depth in our osteoporosis entry.

The second part of the promise — that K2 slows or reverses calcification of blood vessels and heart valves — was tested in its own large, two-year, double-blind randomized trial, designed specifically to settle this question using a hard, imaging-based endpoint, not just a blood biomarker.

This contrast between the two studies illustrates one of the most important principles of critically evaluating evidence in medicine and supplement science: surrogate biomarkers (like dp-ucMGP) are useful for confirming that an intervention "does something" at the biochemical level, but don't always translate into a change in hard endpoints — real, measurable clinical events such as calcification progression visible on imaging, a bone fracture, or a heart attack.

It's worth emphasizing that this doesn't invalidate the bone benefit — Ma and colleagues' meta-analysis relied on a hard endpoint (fracture incidence), not just a bone-density biomarker, which makes that particular conclusion considerably more solid than the cardiovascular hypothesis.

In practice, this means vitamin K2 deserves attention primarily in the context of bone health, especially for people at elevated osteoporosis risk, described in more depth in our osteoporosis entry, where resistance training remains the best-studied, non-pharmacological intervention. Claims of cardiovascular benefit should for now be treated with caution, until equally solid new studies appear.

Vitamin K2 is a rare case of a supplement where one of two popular marketing promises is solidly confirmed (bones), and the other (heart) doesn't hold up against the best-designed available clinical trial. It's a good illustration of why it's worth separating individual claims rather than treating a supplement as one bundled package of benefits.

If you're considering K2 supplementation in the context of bone health, especially as a postmenopausal woman or someone with osteoporosis risk factors, the evidence is convincing. If you're counting on a cardiovascular effect, it's worth lowering expectations — and not treating an improved blood biomarker as a guarantee of improved heart health.